Phathom Pharmaceuticals, Inc. — Director's Dealing 2026

Mar 3, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2026-02-27

Reporting Person: Breedlove Robert Charles (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-27	Common Stock	A	13000	—	Acquired	60068	Direct
2026-02-27	Common Stock	A	2790	—	Acquired	62858	Direct
2026-02-27	Common Stock	F	964	$12.56	Disposed	61894	Direct
2026-02-27	Common Stock	F	414	$12.56	Disposed	61480	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	6945.4	Indirect

Footnotes

F1: Represents restricted stock units ("RSUs") granted on February 27, 2026. 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2: Represents shares issued upon vesting of performance stock units granted to the reporting person on February 27, 2025 based on the achievement of performance criteria determined to be satisfied on February 27, 2026.

F3: Represents shares underlying the performance stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.

F4: Represents shares underlying RSUs that were surrendered by the reporting person to the Issuer upon vesting of such RSU in satisfaction of the Issuer's tax withholding obligation.